BRISTOL-MYERS SQUIBB COMPANY Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $57.00 million for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2015-07-23
- BRISTOL-MYERS SQUIBB COMPANY valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2015-06-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2015-03-31 was $57.00M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month |
|---|---|---|
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-23 | $57.00M 10-Q · filed 2015-07-23 |
| 2015-03-31 | $57.00M 10-Q · filed 2015-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |